Amid Mylan launching an EpiPen generic alternative, the “Fast Money Halftime Report” traders and CNBC’s Jim Cramer share their take on Mylan and the biotech sector.
"Power Lunch" hosts Melissa Lee and Brian Sullivan look at 4 stocks with analyst recommendations, including Alibaba, Express Scripts and more.
Brad Arthur, Black Rock Pharmacy co-owner, shares his take on the rising drug prices and the pharma supply chain.
CNBC’s Meg Tirrell reports the latest on Mylan prices and the drug price blame game.
CNBC contributor Mike Khouw dives into the options for Express Scripts amid the EpiPen pricing controversy.
If Mylan's CEO wants to lower the price of the EpiPen today, she could, Express Scripts' Dr. Steve Miller says.
To blame the healthcare system is what Mylan CEO Heather Bresch told CNBC today in explaining why the price of her company's EpiPen has seen price hikes of 400%. CNBC's Meg Tirrell breaks down the pharma supply chain system.
CNBC's Meg Tirrell reports on the Pharmaceutical Care Management Association's response to Mylan blaming "the middlemen" for its EpiPen price hike.
Vishnu Lekraj, Morningstar senior equity analyst, discusses the role of the pharmacy benefit managers, or PBMs, and whether the "middlemen" are the ones to blame for drug price hikes.
Suzy Welch, LinkedIn contributing editor, discusses Mylan CEO Heather Bresch and what she had to say about the controversy surrounding Mylan's pricing of the EpiPen.
CVS Health's new "excluded" list includes medications used in treatment of patients with cancer, diabetes and hepatitis C.
Shares of Walgreens and Rite Aid skyrocketed around 4 percent amid reports that the FTC is likely to approve Walgreens' acquisition of Rite Aid.
Quarrels have broken out behind the scenes of Anthem's proposed acquisition of Cigna, The Wall Street Journal reported on Sunday.
A new home conception kit offers health insurers a less expensive alternative to pricey fertility treatments.
The pharmacy benefits manager is looking to partner with retail pharmacies that do the best job at keeping diabetes patients healthy.
Some of the names on the move ahead of the open.
Check out the companies making headlines after the bell Monday: Express Scripts, Sanmina, Canadian National Railway and more.
CNBC's Bertha Coombs reports Express Scripts earnings meeting expectations but revenues slightly missing. The company also raising its full-year guidance. Stephanie Link and Steve Grasso on the "Closing Bell" panel also weigh in.
CNBC's Seema Mody looks ahead at the busiest week in earnings season with 186 companies set to report. The "Closing Bell" panel weighs in on what they're watching next week.
Jim Cramer provides his opinion on caller stocks at a rapid pace, including this high-flying tech stock.